AIMD.P AIM4 Ventures

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio Appoints Hui Liu as Director of Biostatistics

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.

“Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice President, Research and Development. “Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move toward our goals.”

Ms. Liu has over 19 years of experience in design, analysis, and reporting all phases of clinical trials across a broad range of therapeutic areas. She brings deep expertise in statistical methodology, including authoring statistical analysis plans, developing programming specifications, and interpreting complex data to support regulatory submissions. In addition to her technical strengths, Ms. Liu has led high-performing teams, managed large accounts, and driven strategic initiatives with a focus on quality, efficiency, and collaboration.

"I’m excited to join Annovis and honored to work with a passionate and driven team,” commented Ms. Liu. “I look forward to applying my statistical expertise to further enhance the integrity of the company’s clinical trials and to help generate high-quality evidence that will support scientific advancement and regulatory success.”

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on , , and .

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at .

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355

Investor Contact:

Alexander Morin, Ph.D.

Director, Strategic Communications

Annovis Bio



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis to Attend the AAIC 2025 with Four Poster Presentations MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s c...

 PRESS RELEASE

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listi...

 PRESS RELEASE

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis to Host Webinar and Live Q&A on June 24, 2025 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience. Webcast Details Date: June 24, 2025Time: 4:30 PM EDTRegistration: During the webcast, Dr. Maccecchini will share...

 PRESS RELEASE

Annovis Provides Corporate Updates and Reports First Quarter 2025 Fina...

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal Phase 3 clinical trial in early AD, with the first participants entering the study ...

 PRESS RELEASE

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio Appoints Hui Liu as Director of Biostatistics MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. “Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch